MX2024002411A - Antagonista biológico que contiene anillos aromáticos, y método para su preparación y su uso. - Google Patents
Antagonista biológico que contiene anillos aromáticos, y método para su preparación y su uso.Info
- Publication number
- MX2024002411A MX2024002411A MX2024002411A MX2024002411A MX2024002411A MX 2024002411 A MX2024002411 A MX 2024002411A MX 2024002411 A MX2024002411 A MX 2024002411A MX 2024002411 A MX2024002411 A MX 2024002411A MX 2024002411 A MX2024002411 A MX 2024002411A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- aromatic ring
- method therefor
- containing biological
- biological antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110988568 | 2021-08-26 | ||
| CN202210633028 | 2022-06-06 | ||
| PCT/CN2022/115068 WO2023025277A1 (zh) | 2021-08-26 | 2022-08-26 | 含芳环类生物拮抗剂、其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002411A true MX2024002411A (es) | 2024-04-05 |
Family
ID=85322470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002411A MX2024002411A (es) | 2021-08-26 | 2022-08-26 | Antagonista biológico que contiene anillos aromáticos, y método para su preparación y su uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240368123A1 (OSRAM) |
| EP (1) | EP4393920A4 (OSRAM) |
| JP (1) | JP2024534111A (OSRAM) |
| KR (1) | KR20240051999A (OSRAM) |
| CN (1) | CN117836294A (OSRAM) |
| AU (1) | AU2022334402A1 (OSRAM) |
| CA (1) | CA3229397A1 (OSRAM) |
| MX (1) | MX2024002411A (OSRAM) |
| TW (1) | TW202328116A (OSRAM) |
| WO (1) | WO2023025277A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7735563B2 (ja) * | 2021-10-21 | 2025-09-08 | ニコヤ セラピューティクス（シャンハイ）カンパニー リミテッド | 二重アンタゴニスト及びその使用 |
| WO2025094214A1 (en) * | 2023-11-02 | 2025-05-08 | Msn Laboratories Private Limited, R&D Center | Process for the preparation of 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl) benzenesulfonamide and its intermediates thereof |
| IT202400000246A1 (it) * | 2024-01-09 | 2025-07-09 | Procos Spa | Processo per la preparazione di sparsentan |
| WO2026021516A1 (zh) * | 2024-07-25 | 2026-01-29 | 深圳信立泰药业股份有限公司 | 一种取代的血管紧张肽和内皮肽受体拮抗剂及其应用 |
| WO2026067819A1 (zh) * | 2024-09-30 | 2026-04-02 | 江苏豪森药业集团有限公司 | 含芳环类生物拮抗剂在制备治疗或预防肾脏疾病药物中的应用 |
| CN119462631A (zh) * | 2024-10-09 | 2025-02-18 | 广东莱佛士制药技术有限公司 | 一种司巴生坦中间体的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06510763A (ja) * | 1991-08-19 | 1994-12-01 | イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー | アンジオテンシン２受容体遮断イミダゾリノン誘導体 |
| US6638937B2 (en) * | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| PT1094816E (pt) * | 1998-07-06 | 2009-03-10 | Bristol Myers Squibb Co | Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina |
| EP1741713A3 (en) * | 1999-12-15 | 2009-09-09 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| ES2259909B1 (es) * | 2005-02-28 | 2007-06-16 | Inke, S.A. | Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de su intermedio de sintesis. |
| BRPI0708507A2 (pt) * | 2006-03-03 | 2011-05-31 | Torrent Pharmaceuticals Ltd | Novos antagonistas de receptores de dupla ação (dara) para os receptores at1 eta |
| WO2007109456A2 (en) * | 2006-03-16 | 2007-09-27 | Pharmacopeia, Inc. | Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists |
| ES2302671T1 (es) * | 2006-08-29 | 2008-08-01 | Teva Pharmaceutical Industries Ltd. | Procedimientos para la sintesis de 5-fenil-1-tritil-1h-tetrazol. |
| JP2011518884A (ja) * | 2008-04-29 | 2011-06-30 | セラヴァンス， インコーポレーテッド | 二重活性抗高血圧剤 |
| DK3222277T3 (da) | 2009-03-31 | 2020-05-11 | Ligand Pharm Inc | Biphenylsulfonamidendothelin- og angiotensin II-receptorantagonist til behandling af glomerulosklerose og IgA-induceret nefropati |
| WO2010135350A2 (en) * | 2009-05-20 | 2010-11-25 | Pharmacopeia, Llc | Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist |
| CN104761548B (zh) * | 2015-04-27 | 2017-09-12 | 梯尔希（南京）药物研发有限公司 | 一种稳定同位素标记的二苯基磺酰胺类药物的制备方法 |
| WO2018005591A1 (en) * | 2016-06-29 | 2018-01-04 | Universite De Montreal | Biarylmethyl heterocycles |
| MA46524A (fr) | 2016-10-13 | 2019-08-21 | Retrophin Inc | Composés de biphényl-sulfonamide destinés au traitement de néphropathies |
| CN112876424B (zh) * | 2019-11-29 | 2023-06-30 | 上海拓界生物医药科技有限公司 | 血管紧张素ii受体及内皮素受体双重拮抗剂 |
| JP7735563B2 (ja) * | 2021-10-21 | 2025-09-08 | ニコヤ セラピューティクス（シャンハイ）カンパニー リミテッド | 二重アンタゴニスト及びその使用 |
| JP2024178482A (ja) * | 2021-11-15 | 2024-12-25 | 株式会社アークメディスン | 化合物、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
-
2022
- 2022-08-26 AU AU2022334402A patent/AU2022334402A1/en active Pending
- 2022-08-26 TW TW111132297A patent/TW202328116A/zh unknown
- 2022-08-26 CN CN202280056242.5A patent/CN117836294A/zh active Pending
- 2022-08-26 MX MX2024002411A patent/MX2024002411A/es unknown
- 2022-08-26 WO PCT/CN2022/115068 patent/WO2023025277A1/zh not_active Ceased
- 2022-08-26 JP JP2024510689A patent/JP2024534111A/ja active Pending
- 2022-08-26 US US18/685,883 patent/US20240368123A1/en active Pending
- 2022-08-26 CA CA3229397A patent/CA3229397A1/en active Pending
- 2022-08-26 EP EP22860623.2A patent/EP4393920A4/en active Pending
- 2022-08-26 KR KR1020247009542A patent/KR20240051999A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240368123A1 (en) | 2024-11-07 |
| JP2024534111A (ja) | 2024-09-18 |
| EP4393920A1 (en) | 2024-07-03 |
| AU2022334402A1 (en) | 2024-02-22 |
| WO2023025277A1 (zh) | 2023-03-02 |
| KR20240051999A (ko) | 2024-04-22 |
| EP4393920A4 (en) | 2025-12-24 |
| CN117836294A (zh) | 2024-04-05 |
| CA3229397A1 (en) | 2023-03-02 |
| TW202328116A (zh) | 2023-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202200519B (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| BR112021024674A2 (pt) | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| HUS1600021I1 (hu) | MEK inhibitorok és módszerek azok felhasználására | |
| JOP20190229A1 (ar) | مركبات تثبط بروتين mcl-1 | |
| BRPI0806789B8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| EP4563150A3 (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer | |
| TW200621762A (en) | Novel compounds | |
| MX2022003649A (es) | Inhibidores del fxia y metodo de preparacion de los mismos y uso farmaceutico de los mismos. | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| BRPI0512974A (pt) | novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| EA200501715A1 (ru) | Замещённые аминокарбоновые кислоты в качестве ингибиторов протеинтирозинфосфатазы-1в | |
| ATE372324T1 (de) | Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen | |
| MX2009003958A (es) | Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso. | |
| EA200501607A1 (ru) | Замещённые фенилалкановые кислоты | |
| EA200501710A1 (ru) | Замещённые карбоновые кислоты | |
| EA201000436A1 (ru) | Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью | |
| MXPA05008690A (es) | Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
| BRPI0716069A2 (pt) | composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio | |
| MX2023005533A (es) | Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina. | |
| TW200806311A (en) | Neuropeptide-2 receptor-agonists | |
| PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| MX2022008091A (es) | Derivado de tetrahidroisoquinolina triciclica, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
| EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
| SE0402925D0 (sv) | Novel Compounds |